FAQ on Soligenix Inc's Pipeline and Strategy as Highlighted in BioMedWire Podcast
Summary
Soligenix Inc's CEO Dr. Christopher Schaber discusses the company's focus on rare disease therapeutics and its Public Health Solutions segment, highlighting a robust late-stage pipeline and significant non-dilutive funding in a recent BioMedWire Podcast episode.
What is Soligenix Inc’s focus as discussed in the BioMedWire Podcast?
Soligenix Inc focuses on developing and commercializing products to treat rare diseases with unmet medical needs, including its Specialized BioTherapeutics and Public Health Solutions segments.
How much funding has Soligenix’s Public Health Solutions segment received?
The Public Health Solutions segment has received over $60 million in non-dilutive U.S. government funding.
What are some of the near-term milestones for Soligenix?
Near-term milestones include a confirmatory Phase 3 trial, active partnership discussions, and the pursuit of strategic opportunities.
What is HyBryte and what is its potential use?
HyBryte (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL), utilizing safe visible light.
What is ThermoVax and how is it used in Soligenix’s vaccine programs?
ThermoVax is Soligenix’s proprietary heat stabilization platform technology used in the development of vaccine programs, including those targeting filoviruses and COVID-19.
Where can I find more information about Soligenix?
More information can be found on Soligenix’s website at https://www.soligenix.com.
What is BioMedWire’s focus?
BioMedWire focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors.
How can I listen to the BioMedWire Podcast episode featuring Soligenix’s CEO?
The podcast episode can be accessed via the link provided in the press release at https://ibn.fm/5HqfY.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 116494